Corrections

Minerva

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7380.75 (Published 11 January 2003) Cite this as: BMJ 2003;326:75

“Stibogluconate, which is used to treat cutaneous leishmaniasis of the new world, is not an arsenic based compound, as stated in the text accompanying the Minerva picture on p 1122 in the issue of 9 November; it is an antimony based compound.”

Footnotes

View Abstract